Concepedia

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

Robert Spiera, Jessica Gordon, Jamie Mersten, Cynthia M. Magro, Mansi B. Mehta, Horatio F. Wildman, Stacey Kloiber, Kyriakos A. Kirou, Stephen Lyman, Mary K. Crow

Annals of the Rheumatic Diseases · 2011 · 174 citations · 28 references

DOIFull text

Open access

Concepts

References

28

Preliminary criteria for the classification of systemic sclerosis (scleroderma)

Alfonse T. Masi · Arthritis & Rheumatism · 1980 · 4.9K citations

, , +12

Cyclophosphamide versus Placebo in Scleroderma Lung Disease

Donald P. Tashkin, Robert M. Elashoff, Philip J. Clements et al. · New England Journal of Medicine · 2006 · 1.7K citations · Full text

, , +10

A multicenter, prospective, randomized, double‐blind, placebo‐controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma

Rachel K. Hoyles, R Ellis, Jessica Wellsbury et al. · Arthritis & Rheumatism · 2006 · 738 citations

, , +13

Stimulatory Autoantibodies to the PDGF Receptor in Systemic Sclerosis

Mariarosaria Santillo, Federica Bevilacqua, Michele Maria Luchetti et al. · New England Journal of Medicine · 2006 · 577 citations · Full text

, , +16

Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis

Craig Daniels, Mark C. Wilkes, Maryanne Edens et al. · Journal of Clinical Investigation · 2004 · 525 citations · Full text

, , +16